Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.
French pharma giant Sanofi will invest some 1 billion euros ($1.05 billion) to establish a new insulin production base in ...
Sanofi is one of the world's top producers of insulin, and the China market for treatment of the illness is huge: Some 140 ...
The French drugmaker said that the investment of about 1 billion euros will enhance the production and manufacturing of ...
Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing ...
Sanofi has announced plans to invest approximately €1bn to build a new insulin production base in China.
Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing ...
Sanofi (SNY) intends to spend about $1.05B building a new insulin manufacturing base in China, Kimberley Kao of The Wall Street Journal ...
Chinese authorities rolled out the red carpet for French pharmaceutical and healthcare giant Sanofi, which plans to invest around 1 billion euros (US$1.05 billion) to build a new insulin plant in ...
Sanofi SAN0.41%increase; green up pointing triangle plans to spend about $1.05 billion building a new insulin manufacturing base in China, the French company’s largest single investment in the ...
The site will be in the Beijing Economic and Technological Development Zone where Sanofi already has production facilities ...